B
ioprocessing-a technique that produces biological material, such as genetically engineered microbial strains and commercially useful chemicals-is big business in the US and growing quickly around the world. An increasing number of pharmaceuticals are now manufactured using bioprocessing techniques. Quality control of these products is a huge issue.
Bioprocessing (and the pharmaceutical industry in general) is highly regulated. The groups that develop guidelines, standards, certifications, validations, and so on aim to ensure extremely high quality levels from the manufacturing plants' pipes, tanks, and valves all the way through the finished product, with a focus on cleanability, sterility, and reproducibility.
However, in the past 10 or so years, the industry has been pushing for increased plant efficiency and manufacturing globalization, and is now focusing on plant automation. The groups involved in standardization, certification, and validation have been working hard to keep up with the industry's needs and stay in sync. A brief discussion of these organizations with some history gives additional perspective on the current state of biopharmaceutical plant standards and regulation. Figure 1 depicts the purview of the groups that influence biopharmaceutical guidelines, standards, and regulations. The influential agents (ovals) cover different levels of the plant and manufacturing process, from base-level components to the actual production process. Entities such as suppliers, distributors, and drug manufacturers that are involved with development of each component, piece of equipment, or drug are listed above their area of interest.
STANDARDS OVERVIEW OF THE ORGANIZATIONS
The picture of the organizations shown in Figure 1 is simplified in that these are the ones with which USbased companies predominantly deal. Each global region typically has its own guidelines and standards for biopharmaceutical processes, and each country has its own regulation body equivalent to the US Food and Drug Administration (FDA). The more that these national bodies can use internationally recognized standards, the fewer the hurdles that biopharmaceutical plants operating globally must overcome.
The Bio-process Systems Alliance (BPSA), formed in 2005, is a trade association that pushes single-use (disposable) materials used in plants, such as bags, filtration products, and connectors. The BioPhorum Operations Group (BPOG), another trade group, covers all types of components and equipment. Both groups support their members as the industry changes and are involved with creating standards and best practices.
The American Society of Mechanical Engineers Bioprocessing Equipment Group (ASME-BPE) maintains the official ANSI international standard developed for biopharmaceutical manufacturing equipment design and construction.
The International Society for Pharmaceutical Engineering (ISPE) focuses on facilitating communication between the pharmaceutical industry and regulators to develop quality standards; its work butts up against several International Organization for Standardization (ISO) areas.
And then there's the FDA, which covers drug manufacturing processes, product quality, and distribution to customers. The FDA must validate and approve the manufacturing process before production begins and requires that each drug batch be tested for quality during manufacturing. Multiple samples are taken, tested, and documented throughout the process. If there's any variation in the expected quality, the product is pulled.
The FDA's "Guidance for Industry on Process Validation: General Principles and Practices; Availability" (www .federalregister.gov/documents/2011 / 0 1 / 2 5/ 2 0 1 1-14 3 7/g u i d a n c e -f o r -i ndu s t r y-on-pr o ce s s-v a l id at ion -genera l-principles-and-practices -availability) offers a risk-based lifecycle approach to process validation. The FDA promotes the use of quality management systems (as in ISO 9001) but doesn't indicate how this extends to automation via software. Nonetheless, IEEE and ISO have developed software quality and lifecycle standards that address the riskbased lifecycle approach to software development.
Because the US government asks its agencies to use consensus-based standards rather than create regulations, the FDA typically relies on recognized standards-developing organizations (SDOs), such as the ASME, ISPE, ISO, and IEEE, to define the standards, and then uses those. The reason it can feel as though the FDA's control is everywhere is because each time something changes in a plant, such as the material of a seal or the type of component that takes a sample, the FDA requires either partial revalidation or revalidation of the entire manufacturing process. In essence, it requires that the manufacturer revalidate that the product will retain its purity and efficacy. Each validation can cost more than $100,000, and for some products, the time lost waiting to restart a plant after validation can result in millions of dollars in losses. It's this reason that change-no matter how much of an improvement-is often resisted after a plant starts running.
BIOPHARMACEUTICAL STANDARDS AND CERTIFICATIONS: HOW DID WE GET HERE?
In 1989, an ad hoc committee on bioprocessing equipment was established to create a standard for bioprocessing equipment. The committee began by creating guidelines that covered the mechanical portion of bioprocessing in factories, specifying how to best design and build equipment used in biopharmaceuticals production. This standard was originally a set of best practices designed to ensure both manufacturing safety and consistent product quality and purity. In the mid-1990s, ASME stepped in and requested that the guidelines be turned into a true set of standards that it could adopt, and in 1997, the first edition of the ASME-BPE standard was approved and published. This standard, although very thorough and well regarded, hasn't been universally adopted. Many countries or regions have their own standards, which causes significant issues for companies that want to use the same factory equipment, design, and processes in multiple global locations. Internationalization issues, with respect to language, measurements, and needs, consistently push the groups to reassess and modify the ASME-BPE standard. But this issue isn't the main thrust of the story.
For the past 10 years, the ASME-BPE has been working on a certification process for all components used to construct biopharmaceutical plants. The effort is designed to prevent plant builders from purchasing substandard parts from new manufacturers around the world. The effort started with simple parts, such as tubing and fittings, and is currently focusing on certification for gaskets. Each of these parts brings up complicated issues associated with the parts' material composition and specifics about allowable design features. And each decision influences other standards and regulatory agencies, all the way to the FDA. ASME-BPE and other certification authorities continue to march through this process. In our opinion, they have yet to hit some of the most interesting issues. Although biopharmaceutical plants predominantly comprised nearly static plumbing of tanks, pipes, and valves, automation has been sneaking into these plants.
What used to be a personneloperated and -managed process is becoming run by automated software: pneumatic actuators on the valves are now predominantly opened and closed by software housed in a control room. Software continuously monitors hundreds of sensors (such as thermometers, blood gas analyzers, and nutrient monitors) to ensure safety and cleanliness, and detect issues such as spillage. Through Bluetooth and Wi-Fi links, the biopharmaceutical processes are now monitored less by plant operators walking around the floor and more by one or a few operators in a control room looking at displays and warning systems. Future steps will likely tie the control of the process to bioreactors and chromatography skids that will allow for continuous monitoring of product quality. In addition, the manufacturing process is moving from discrete batches to a continuous flow of product. Although automation is being adopted more slowly than other industries due to a general fear of walking away and letting the control software take over, the cost of errors for some organizations is just too high. Automation's upside, especially in aseptic processing, is that you prevent as much human intervention as possible to avoid contamination. But remember, each time a drug manufacturer makes a major change of this kind, it must revalidate the process with the FDA.
AUTOMATION SOFTWARE
Some more sophisticated plants are using commercial products like Rockwell What used to be a personneloperated and -managed process is becoming run by automated software.
STANDARDS
Automations' DeviceNet for communication among sensors, valve controllers, and the control room. These products typically have equipment and facility certifications from the EU, such as ATEX and IECEx, and from the organizations comprising the Australian standards and conformance infrastructure that indicate their reliability or ability to withstand harsh manufacturing conditions. They also have significant redundancy and robustness requirements. The answers aren't obvious. However, it's clear that biopharmaceutical plant automation will continue. When control systems-software or electronics-are altered, careful testing must be performed, because as many of us have experienced from software updates in less critical situations, they don't always go as planned. The cost of "mistakes" in this arena is high.
